106 related articles for article (PubMed ID: 3262668)
1. Tryptophan degradation in transplanted tumor cells undergoing rejection.
Yoshida R; Park SW; Yasui H; Takikawa O
J Immunol; 1988 Oct; 141(8):2819-23. PubMed ID: 3262668
[TBL] [Abstract][Full Text] [Related]
2. IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection.
Takikawa O; Habara-Ohkubo A; Yoshida R
J Immunol; 1990 Aug; 145(4):1246-50. PubMed ID: 2116480
[TBL] [Abstract][Full Text] [Related]
3. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
Yoshida R; Yoneda Y; Kuriyama M; Kubota T
J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
[TBL] [Abstract][Full Text] [Related]
4. The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site.
Yoneda Y; Yoshida R
J Immunol; 1998 Jun; 160(12):6012-7. PubMed ID: 9637516
[TBL] [Abstract][Full Text] [Related]
5. Activity of tumor-associated lymphoid cells at short intervals after administration of irradiated syngeneic and allogeneic tumor cells.
Schick B; Berke G
J Immunol; 1977 Mar; 118(3):986-91. PubMed ID: 321684
[TBL] [Abstract][Full Text] [Related]
6. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
7. Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogeneic mouse: interferon-gamma is the inducer.
Takikawa O; Habara-Ohkubo A; Yoshida R
Adv Exp Med Biol; 1991; 294():437-44. PubMed ID: 1772076
[TBL] [Abstract][Full Text] [Related]
8. Two types of allograft-induced cytotoxic macrophage, one against allografts and the other against syngeneic or allogeneic tumor cells.
Yoneda Y; Tashiro-Yamaji J; Kubota T; Yoshida R
Microbiol Immunol; 2008 Jul; 52(7):349-56. PubMed ID: 18667033
[TBL] [Abstract][Full Text] [Related]
9. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
Dennert G; Anderson CG; Warner J
J Immunol; 1986 Jun; 136(11):3981-6. PubMed ID: 3517162
[TBL] [Abstract][Full Text] [Related]
10. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
11. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated lymphoid cells: analysis of host cells that bind to syngeneic and allogeneic tumor cells shortly after tumor administration.
Schick B; Berke B
Transplant Proc; 1977 Mar; 9(1):1157-60. PubMed ID: 867485
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous rejection of intradermally transplanted non-engineered tumor cells by neutrophils and macrophages from syngeneic strains of mice.
Ibata M; Takahashi T; Shimizu T; Inoue Y; Maeda S; Tashiro-Yamaji J; Okada M; Ueda K; Kubota T; Yoshida R
Microbiol Immunol; 2011 Oct; 55(10):726-35. PubMed ID: 21806674
[TBL] [Abstract][Full Text] [Related]
14. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
Rakhmilevich AL
Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
[TBL] [Abstract][Full Text] [Related]
15. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
[TBL] [Abstract][Full Text] [Related]
16. Antigenic cancer cells that escape immune destruction are stimulated by host cells.
Seung LP; Seung SK; Schreiber H
Cancer Res; 1995 Nov; 55(21):5094-100. PubMed ID: 7585557
[TBL] [Abstract][Full Text] [Related]
17. Requirements for T cells in alloantigen-induced generation of non-T cell-mediated cytotoxicity against syngeneic mouse sarcoma cells.
Paciucci PA; Macphail S; Bach FH; Zarling JM
J Immunol; 1980 Jul; 125(1):36-9. PubMed ID: 6155401
[TBL] [Abstract][Full Text] [Related]
18. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
Giovarelli M; Santoni A; Forni G
J Immunol; 1985 Nov; 135(5):3596-603. PubMed ID: 3930610
[TBL] [Abstract][Full Text] [Related]
19. T killer cells play a role in allogeneic bone marrow graft rejection but not in hybrid resistance.
Dennert G; Anderson CG; Warner J
J Immunol; 1985 Dec; 135(6):3729-34. PubMed ID: 3905963
[TBL] [Abstract][Full Text] [Related]
20. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.
Mellor AL; Sivakumar J; Chandler P; Smith K; Molina H; Mao D; Munn DH
Nat Immunol; 2001 Jan; 2(1):64-8. PubMed ID: 11135580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
